Business
Xeris Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline Progress
GVOKE™ PFS net sales of $1.6 million in Q4 2019 GVOKE HypoPen™ on track for planned launch in July 2020 All current clinical programs expected to report
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":"\nGVOKE™ PFS net sales of $1.6 million in Q4 2019\n\n\nGVOKE HypoPen™ on track for planned launch in July 2020 \n\n\nAll current clinical programs expected to report topline results in 1H 2020 \n\n\nConference call and webcast today at 8:30 a.m. ET\n\n CHICAGO--(BUSINESS WIRE)--\nXeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infusible drug formulations, today announced financial results for the fourth quarter and full year 2019, as well as pipeline and corporate highlights.\n\n\n“2019 was a very busy and transformational year for Xeris. With our first product approved by the FDA in September 2019, we transitioned from being a development company to a commercial organization validating our novel XeriSol™ formulation technology, while progressing several pipeline programs in the clinic. Because Gvoke PFS is such an important innovation for people with diabetes, our time and attention in the fourth quarter was dedicated to securing managed care access for Gvoke PFS and Gvoke HypoPen to set us up for success in 2020,” said Paul R. Edick, Chairman and CEO of Xeris. “In 2020, we are intensely focused on commercial execution by replacing the current glucagon emergency kits with Gvoke PFS in the hands and homes of patients, as well as preparing for the launch of Gvoke HypoPen in July. In addition, we expect to report topline data from four clinical programs in the first half, followed by discussions with the regulatory agencies regarding paths forward.”\n\n\nFourth Quarter 2019 Highlights and Recent Events\n\n\nApproved Products\n\n\n‒ Xeris’ Gvoke pre-filled syringe (PFS), its ready-to-use, room-temperature stable liquid glucagon for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above, became available in November 2019. In the fourth quarter of 2019, Xeris’ 80-person field-based team worked to secure formulary coverage and started to call on healthcare professionals. As of February 28, 2020, approximately 65% of commercially insured lives have unrestricted access to Gvoke.\n\n\n‒ The Company is on track for its planned launch of Gvoke HypoPen, its liquid stable glucagon in an auto-injector, in July 2020.\n\n\nOther Ready-to-use Glucagon Program...